Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arthritis
CombinatoRx Announces Initiation of Phase 2b Clinical Study of CRx-102 in Knee Osteoarthritis
October 8th, 2007
CombinatoRx, Incorporated (NASDAQ: CRXX) announced that it has dosed the first patient in a Phase 2b clinical trial in knee osteoarthritis with CRx-102, an oral synergistic combination drug candidate in development for immuno-inflammatory diseases. The trial, COMET-1 (CRx-102 Osteoarthritis Multi-center Evaluation Trial), is designed to evaluate the efficacy of CRx-102 compared to placebo in subjects with symptomatic knee osteoarthritis. "CRx-102 has already demonstrated clinical efficacy in three Phase 2a clinical studies, including hand osteoarthritis and rheumatoid arthritis," commented Daniel Grau, Chief Operating Officer of CombinatoRx. "We remain on-track to...
Source: Biotech Business Week (2007-10-08)
|
